


RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



IN RE APPLICATION OF: William J. Curatolo, et al.

APPLICATION NO.: 009/770,562

FILING DATE: January 26, 2001

TITLE: Solid Pharmaceutical Dispersions with Enhanced Bioavailability

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Examiner: B. Fubara

S/Pfizer Art W/att
Group Art Unit 1615
I hereby certify that this correspondence
is being deposited with the United States
Postal Service as First Class Mail in an
envelope addressed to: Assistant Commissioner
for Patents, Washington, D.C. 20231 on

this 27 day of March 2002

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is noted that two of the references are in Japanese. English translations have been requested and will be submitted as soon as Applicants receive them.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: March 27, 2002

James T. Jones
James T. Jones
Attorney for Applicant(s)
Reg. No. 30,561

Pfizer Inc.
Patent Department, Box 519
Eastern Point Road
Groton, CT 06340
(860) 441-4903